Impact of vascular calcification on cardiovascular mortality in hemodialysis patients: Clinical significance, mechanisms and possible strategies for treatment

Renal Replacement Therapy

Volumn 3, Issue 1, 2017, Pages

  Ohtake, Takayasu ^a   Kobayashi, Shuzo ^a  

^a SHONAN KAMAKURA GENERAL HOSPITAL   (Japan)

Author keywords

Cardiovascular mortality; Hemodialysis; Phosphate; Phosphate binder; Vascular calcification

Indexed keywords

EID: 85030667530     PISSN: None     EISSN: 20591381     Source Type: Journal    
DOI: 10.1186/s41100-017-0094-y     Document Type: Review

References (130)

1. Kobayashi S. Cardiovascular events in chronic kidney disease (CKD) - an importance of vascular calcification and microcirculatory impairment. Renal Replacement Therapy. 2016;2:55. doi: 10.1186/s41100-016-0062-y.
2. Ohtake T, Kobayashi S, Moriya H, Negishi K, Okamoto K, Maesato K, et al. High prevalence of occult coronary artery stenosis in patients with chronic kidney disease at the initiation of renal replacement therapy: an angiographic examination. J Am Soc Nephrol. 2005;16:1141-8.
3. Joki N, Hase H, Nakamura R, Yamaguchi T. Onset of coronary artery disease prior to initiation of haemodialysis in patients with end stage renal disease. Nephrol Dial Transplant. 1997;12:718-23.
4. Lindner A, Charra B, Sherrard DJ, Scribner BH. Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med. 1974;290:697-701.
5. Möncheberg JG. Uber die reine Mediaverkalkung der Extremitätenarterien und ihr verhalten zur Arterosklerose. Virchow Arch Pathol Anat. 1903;171:141-67.
6. Blacher J, Guerin AP, Pannier B, Marchais SJ, London GM. Arterial calcifications, arterial stiffness, and cardiovascular risk in ESRD. Hypertension. 2001;38:938-42.
7. London GM. Cardiovascular calcifications in uremic patients: clinical impact on cardiovascular function. J Am Soc Nephrol. 2003;14:S305-9.
8. Block GA, Raggi P, Bellasi A, Kooienga L, Spiegel DM. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int. 2007;71:438-41.
9. Matsuoka M, Iseki K, Tamashiro M, Fujimoto N, Higa N, Touma T, et al. Impact of high coronary artery calcification score (CACS) on survival in patients on chronic hemodialysis. Clin Exp Nephrol. 2004;8:54-8.
10. Ohtake T, Ishioka K, Honda K, Oka M, Maesato K, Mano T, et al. Impact of coronary artery calcification in hemodialysis patients: risk factors and associations with prognosis. Hemodial Int. 2010;14:218-25.
11. Shantouf RS, Budoff MJ, Ahmadi N, Ghaffari A, Flores F, Gopal A, et al. Total and individual coronary artery calcium scores as independent predictors of mortality in hemodialysis patients. Am J Nephrol. 2010;31:419-25.
12. Shimoyama Y, Tsuruta Y, Niwa T. Coronary artery calcification score is associated with mortality in Japanese hemodialysis patients. J Ren Nutr. 2012;22:139-42.
13. Wilkieson T, Rahman MO, Gangii AS, Voss M, Ingram AJ, Ranganath N, et al. Coronary artery calcification, cardiovascular events, and death: a prospective cohort study of incident patients on hemodialysis. Canadian J Kidney Disease. 2015;2:29.
14. Okuno S, Ishimura E, Kitatani K, Fujino Y, Kohno K, Maeno Y, et al. Presence of abdominal aortic calcification is significantly associated with all-cause and cardiovascular mortality in maintenance hemodialysis patients. Am J Kidney Dis. 2007;49:417-25.
15. Verbeke F, Van Biesen W, Honkanen E, Wikstrom B, Jensen PB, Krzesinski JM, et al. CORD study investigators: prognostic value of aortic stiffness and calcification for cardiovascular events and mortality in dialysis patients: outcome of the Calcification Outcome in Renal Disease (CORD) study. Clin J Am Soc Nephrol. 2011;6:153-9.
16. Noordzij M, Cranenburg EM, Engelsman LF, Hermans MM, Boeschoten EW, Brandenburg VM, Bos WJ, et al. NECOSAD study group: progression of aortic calcification is associated with disorders of mineral metabolism and mortality in chronic dialysis patients. Nephrol Dial Transplant. 2011;26:1662-9.
17. Inoue T, Ogawa T, Ishida H, Ando Y, Nitta K. Aortic arch calcification evaluated on chest X-ray is a strong independent predictor of cardiovascular events in chronic hemodialysis patients. Heart Vessels. 2012;27:135-42.
18. Ohya M, Otani H, Kimura K, Saika Y, Fujii R, Yukawa S, et al. Vascular calcification estimated by aortic calcification area index is a significant predictive parameter of cardiovascular mortality in hemodialysis patients. Clin Exp Nephrol. 2011;15:877-83.
19. Komatsu M, Okazaki M, Tsuchiya K, Kawaguchi H, Nitta K. Aortic arch calcification predicts cardiovascular and all-cause mortality in maintenance hemodialysis patients. Kidney Blood Press Res. 2014;39:658-67.
20. Nakayama M, Ura Y, Nagata M, Okada Y, Sumida Y, Nishida K, et al. Carotid artery calcification at the initiation of hemodialysis is a risk factor for cardiovascular events in patients with end-stage renal disease: a cohort study. BMC Nephrol. 2011;12:56.
21. Ogata H, Fukagawa M, Hirakata H, Kaneda H, Kagimura T, Akizawa T, LANDMARK study group: design and baseline characteristics of the LANDMARK study. Clin Exp Nephrol. 2016. in press.
22. Ohtake T, Oka M, Ikee R, Mochida Y, Ishioka K, Moriya H, et al. Impact of lower limbs' arterial calcification on the prevalence and severity of PAD in patients on hemodialysis. J Vasc Surg. 2011;53:676-83.
23. Raggi P, Bellasi A, Ferramosca E, Islam T, Muntner P, Block GA. Association of pulse wave velocity with vascular and valvular calcification in hemodialysis patients. Kidney Int. 2007;71:802-7.
24. Haydar AA, Covic A, Colhoun H, Rubens M, Goldsmith DJ. Coronary artery calcification and aortic pulse wave velocity in chronic kidney disease patients. Kidney Int. 2004;65:1790-4.
25. Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest. 2011. doi: 10.1172/JCI46122.
26. Shanahan CM. Mechanisms of vascular calcification in CKD-evidence for premature ageing? Nat Rev Nephrol. 2013;9:661-70.
27. Yao Y, Bennett BJ, Wang X, Rosenfeld ME, Giachelli C, Lusis AJ, et al. Inhibition of bone morphogenic protein protects against atherosclerosis and vascular calcification. Circ Res. 2010;107:485-94.
28. Reynolds JL, Joannides AJ, Skepper JN, McNair R, Schurgers LJ, Proudfoot D, et al. Human vascular smooth muscle cells undergo vesicle-mediated calcification in response to changes in extracellular calcium and phosphate concentrations: a potential mechanism for accelerated vascular calcification in ESRD. J Am Soc Nephrol. 2004;15:2857-67.
29. Kapustin AN, Davies JD, Reynolds JL, McNair R, Jones GT, Sidibe A, et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ Res. 2011;109:e1-e212.
30. Palaniswamy C, Sekhri A, Aronow WS, Kalra A, Peterson SJ. Association of warfarin use with valvular and vascular calcification: a review. Clin Cardiol. 2011;34:74-81.
31. Lomashvili KA, Garg P, Narisawa S, Millan JL, O'Neill WC. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcifications. Kidney Int. 2008;73:1024-30.
32. Narisawa S, Harmey D, Yadav MC, O'Neill WC, Hoylaerts MF, Millan JL. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res. 2007;22:1700-10.
33. O'Neill WC. Pyrophosphate, alkaline phosphatase, and vascular calcification. Circ Res. 2006;99, e2.
34. Kuro-o M. A phosphate-centric paradigm for pathophysiology and therapy of chronic kidney disease. Kidney Int Suppl. 2013;3:420-6.
35. Schinke T, Amendt C, Trindl A, Pöschke O, Müller-Esterl W, Jahnen-Dechent W. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J Biol Chem. 1996;271:20789-96.
36. Reynolds JL, Skepper JN, McNair R, Kasama T, Gupta K, Weissberg PL, et al. Multifunctional roles for serum protein fetuin-a in inhibition of human vascular smooth muscle cell calcification. J Am Soc Nephrol. 2005;16:2920-30.
37. Ketteler M, Bongartz P, Westenfeld R, Wildberger JE, Mahnken AH, Böhm R, et al. Association of low fetuin-A (AHSG) concentrations in serum with cardiovascular mortality in patients on dialysis: a cross-sectional study. Lancet. 2003;361:827-33.
38. Smith ER, Cai MM, McMahon LP, Pedegogos E, Toussaint ND, Brumby C, et al. Serum fetuin-A concentration and fetuin-A-containing carciprotein particles in patients with chroic inflammatory disease and renal failure. Nephrology (Carlton). 2013;18:215-21.
39. Smith ER, Ford ML, Tomlinson LA, Rajkumar C, McMahon LP, Holt SG. Phosphorylated fetuin-A-containing carciprotein particles are associated with aortic stiffness and a procalcific milieu in patients with pre-dialysis CKD. Nephrol Dial Transplant. 2012;27:1957-66.
40. Hamano T, Matsui I, Mikami S, Tomida K, Fujii N, Imai E, et al. Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. 2010;21:1998-2007.
41. Lyemere VP, Proudfoot D, Weissberg PL, Shanahan CM. Vascular smooth muscle cell phenotypic plasticity and the regulation of vascular calcification. J Intern Med. 2006;260:192-210.
42. Byon CH, Javed A, Dai Q, Kappes JC, Clemens TL, Darley-Usmar VM. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J Biol Chem. 2008;283:15319-27.
43. Li X, Giachelli CM. Sodium-dependent phosphate cotoransporters and vascular calcification. Curr Opin Nephrol Hypertens. 2007;16:325-8.
44. Voelkl J, Alesutan I, Leibrock CB, Quintanilla-Martinez L, Kuhn V, Feger M, et al. Spironolactone ameliorates PIT1-dependent vascular osteoinduction in klotho-hypomorphic mice. J Clin Invest. 2013;123:812-22.
45. Shigematsu T, Kono T, Satoh K, Yokoyama K, Yoshida T, Hosoya T, et al. Phosphate overload accelerates vascular calcium deposition in end-stage renal disease patients. Nephrol Dial Trasplant. 2003;18 Suppl 3:iii86-9.
46. Shroff RC, McNair R, Skepper JN, Figg N, Schurgers LJ, Deanfield J, et al. Chronic mineral dysregulation promotes vascular smooth muscle cell adaptation and extracellular matrix calcification. J Am Soc Nephrol. 2010;21:103-12.
47. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. Am J Kidney Dis. 2003;42:303-9.
48. Taki K, Takayama F, Tsuruta Y, Niwa T. Oxidative stress, advanced glycation end product, and coronary artery calcification in hemodialysis patients. Kidney Int. 2006;70:218-24.
49. McCullough PA, Soman S. Cardiovascular calcification in patients with chronic renal failure: are we on target with this risk factor? Kidney Int Suppl. 2004;90:S18-24.
50. McCullough PA. Effect of lipid modification on progression of coronary calcification. J Am Soc Nephrol. 2005;16 Suppl 2:S115-9.
51. Shantouf R, Kovesdy CP, Kim Y, Ahmadi N, Luna A, Luna C, et al. Association of serum alkaline phosphatase with coronary artery calcification in maintenance hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:1106-14.
52. Barreto DV, Barreto Fde C, Carvalho AB, Cuppari L, Draibe SA, Dalboni MA, et al. Association of changes in bone remodeling and coronary artery calcification in hemodialysis patients: a prospective study. Am J Kidney Dis. 2008;52:1139-50.
53. Kirkpantur A, Altun B, Hazirolan T, Akata D, Arici M, Kirazli S, et al. Association among serum fetuin-A level, coronary artery calcification, and bone mineral densitometry in maintenance hemodialysis patients. Art Organs. 2009;33:844-54.
54. Moe SM, Reslerova M, Ketteler M, O'Neill K, Duan D, Koczman J, et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 2005;67:2295-304.
55. Mehrotra R, Westenfeld R, Christenson P, Budoff M, Ipp E, Takasu J, et al. Serum fetuin-A in nondialyzed patients with diabetic nephropathy: relationship with coronary artery calcification. Kidney Int. 2005;67:1070-7.
56. Kim SC, Kim HW, Oh SW, Tang HN, Kim MG, Jo SK, et al. Low iPTH can predict vascular and coronary calcifications in patients undergoing peritoneal dialysis. Nephron Clin Prac. 2011;117:c113-9.
57. London GM, Marty C, Marchais SJ, Guerin AP, Metivier F, de Vernejoul MC. Arterial calcifications and bone histomorphometry in end-stage renal disease. J Am Soc Nephrol. 2004;15:1943-51.
58. Adragao T, Herberth J, Monier-Faugere MC, Branscum AJ, Ferreira A, Frazao JM, et al. Low bone volume - a risk factor for coronary calcification in hemodialysis patients. Clin J Am Soc Nephrol. 2009;4:450-5.
59. Coen G, Ballanti P, Mantilla D, Manni M, Lippi B, Pierantozzi A, et al. Bone turnover, osteopenia and vascular calcifications in hemodialysis patients. Am J Nephrol. 2009;29:145-52.
60. Kahn AM, Chirinos JA, Litt H, Yang W, Rosas SE. FGF-23 and the progression of coronary arterial calcification in patients new to dialysis. Clin J Am Soc Nephrol. 2012;7:2017-22.
61. Ozkok A, Kekik C, Karahan GE, Sakaci T, Ozel A, Unsal A, et al. FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients. BMC Nephrol. 2013;14:241.
62. Nasrallah MM, El-Shehaby AR, Salem MM, Osman NA, El Sheikh E, Sharaf El Din UA. Fibroblast growth factor-23 (FGF-23) is independently correlated to aortic calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:2679-85.
63. Jean G, Bresson E, Terrat JC, Vanel T, Hurot JM, Lorriaux C, et al. Peripheral vascular calcification in long-hemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2009;24:948-55.
64. Oka M, Ohtake T, Mochida Y, Ishioka K, Maesato K, Moriya H, et al. Correlation of coronary artery calcification with pre-hemodialysis bicarbonate levels in patients on hemodialysis. Ther Apher Dial. 2012;16:267-71.
65. Qunibi WY. Dyslipidemia and progression of cardiovascular calcification (CVC) in patients with end-stage renal disease (ESRD). Kidney Int Suppl. 2005;95:S43-50.
66. Greif M, Arnoldt T, von Ziegler F, Ruemmler J, Becker C, Wakili R, et al. Lipoprotein (a) is independently correlated with coronary artery calcification. Eur J Intern Med. 2013;24:75-9.
67. Ozkok A, Caliskan Y, Sakaci T, Erten G, Karahan G, Ozel A, et al. Osteoprotegerin/RANKL axis and progression of coronary artery calcification in hemodialysis patients. Clin J Am Soc Nephrol. 2012;7:965-73.
68. Barreto DV, Barreto FC, Carvalho AB, Cuppari L, Cendoroglo M, Draibe SA, et al. Coronary calcification in hemodialysis patients: the contribution of traditional and uremia-related risk factors. Kidney Int. 2005;67:1576-82.
69. Morena M, Dupuy AM, Jaussent I, Vernhet H, Gahide G, Klouche K, et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant. 2009;24:3389-97.
70. Malluche HH, Blomquist G, Monier-Faugere MC, Cantor TL, Davenport DL. High parathyroid hormone level and osteoporosis predict progression of coronary artery calcification in patients on dialysis. J Am Soc Nephrol. 2015;26:2534-44.
71. Wang YN, Sun Y, Wang Y, Jia YL. Serum S100A12 and progression of coronary artery calcification over 4 years in hemodialysis patients. Am J Nephrol. 2015;42:4-13.
72. Zhang H, Wang LJ, Si DL, Wang C, Yang JC, Jiang P, et al. Correlation between osteocalcin-positive endothelial progenitor cells and spotty calcification in patients with coronary artery disease. Clin Exp Pharmacol Physiol. 2015;42:734-9.
73. Wang M, Li H, You L, Yu X, Zhang M, Zhu R, et al. Association of serum phosphate variability with coronary artery calcification among hemodialysis patients. PLoS One. 2014;9, e93360.
74. Jung HH, Kim SW, Han H. Inflammation, mineral metabolism and progressive coronary artery calcification in patients on haemodialysis. Nephrol Dial Transplant. 2006;21:1915-20.
75. Stompór T, Pasowicz M, Sullowicz W, Dembinska-Kiec A, Janda K, Wöjcik K, et al. An association between coronary artery calcification score, lipid profile, and selected markers of chronic inflammation in ESRD patients treated with peritoneal dialysis. Am J Kidney Dis. 2003;41:203-11.
76. Izumi M, Morita S, Nishian Y, Miyamoto T, Kasumoto H, Oue M, et al. Switching from calcium carbonate to sevelamer hydrochloride has suppressive effects on the progression of aortic calcification in hemodialysis patients: assessment using plain chest X-ray films. Ren Fail. 2008;30:952-8.
77. Koleganova N, Piecha G, Ritz E, Schirmacher P, Müller A, Meyer HP, et al. Arterial calcification in patients with chronic kidney disease. Nephrol Dial Transplant. 2009;24:2488-96.
78. Riminucci M, Collins MT, Fedarko NS, Cherman N, Corsi A, White KE, et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest. 2003;112:683-92.
79. Kuro-o M, Matsumura Y, Aizawa H, Kawaguchi H, Suga T, Utsugi T, et al. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature. 1997;390:45-51.
80. Lim K, Lu TS, Molostvov G, Lee C, Lam FT, Zehnder D, et al. Vascular klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor 23. Circulation. 2012;125:2243-55.
81. Shiraki-Iida T, Iida A, Nabeshima Y, Anazawa H, Nishikawa S, Noda M, et al. Improvement of multiple pathophysiological phenotypes of klotho (kl/kl) mice by adenovirus-mediated expression of the klotho gene. J Gene Med. 2000;2:233-42.
82. Nakano-Kurimoto R, Ikeda K, Uraoka M, Nakagawa Y, Yutaka K, Koide M, et al. Replicative senescence of vascular smooth muscle cells enhances the calcification through initiating the osteoblastic transition. Am J Physiol Heart Circ Physiol. 2009;297:H1673-84.
83. 536 phosphorylation. Diabetes. 2011;60:1907-16.
84. Scialla JJ, Lau WL, Reilly MP, Isakova T, Yang HY, Crouthamel MH, et al. Fibroblast growth factor 23 is not associated with and does not induce arterial calcification. Kidney Int. 2013;83:1159-68.
85. Chertow GM, Raggi P, Chasan-taber S, Bommer J, Holzer H, Burke SK. Determinants of progressive vascular calcification in hemodialysis patients. Nephrol Dial Transplant. 2004;19:1489-96.
86. Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int. 2002;62:245-52.
87. Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, et al. Coronary artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 2000;342:1478-83.
88. Guerin AP, London GM, Marchais SJ, Metivier F. Arterial stiffness and vascular calcifications in end-stage renal disease. Nephrol Dial Transplant. 2000;15:1014-21.
89. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int. 2005;68:1815-24.
90. Kakuta T, Tanaka R, Hyodo T, Suzuki H, Kanai G, Nagaoka M, et al. Effect of sevelamer and calcium-based phosphate binders on coronary artery calcification and accumulation of circulating advanced glycation end products in hemodialysis patients. Am J Kidney Dis. 2011;57:422-31.
91. Shantouf R, Ahmadi N, Flores F, Tiano J, Gopal A, Kalantar-Zadeh K, et al. Impact of phosphate binder type on coronary artery calcification in hemodialysis patients. Clin Nephrol. 2010;74:12-8.
92. Asmus HG, Braun J, Krause R, Brunkhorst R, Holzer H, Schulz W, et al. Two year comparison of sevelamer and calcium carbonate effects on cardiovascular calcification and bone density. Nephrol Dial Transplant. 2005;20:1653-61.
93. Vlassara H, Uribarri J, Cai W, Goodman S, Pyzik R, Post J, et al. Effects of sevelamer on HbA1c, inflammation, and advanced glycation end products in diabetic kidney disease. Clin J Am Soc Nephrol. 2012;7:934-42.
94. Guida B, Cataldi M, Riccio E, Grumetto L, Pota A, Borrelli S, et al. Plasma p-cresol lowering effect of sevelamer in peritoneal dialysis patients: evidence from a Cross-Sectional Observational Study. PLoS One. 2013;8, e73558.
95. Zhang Q, Li M, Lu Y, Li H, Gu Y, Hao C, et al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract. 2010;115:c259-67.
96. Akizawa T. Importance of serum phosphate management and feature of phosphate binder in hemodialysis patients. Therapeutic Research. 2014;35:285-91 (in Japanese).
97. Daugirdas JT, Finn WF, Emmett M, Chertow GM. Frequent Hemodialysis Network Trial Group. The phosphate binder equivalent dose. Semin Dial. 2011;24:41-9.
98. Ohtake T, Kobayashi S, Oka M, Furuya R, Iwagami M, Tsutsumi D, et al. Lanthanum carbonate delays progression of coronary artery calcification compared with calcium-based phosphate binders in patients on hemodialysis: a pilot study. J Cardiovasc Pharm Ther. 2013;18:439-46.
99. Toussaint ND, Lau KK, Polkinghorne KR, Kerr PG. Attenuation of aortic calcification with lanthanum carbonate versus calcium-based phosphate binders in haemodialysis: a pilot randomized controlled trial. Nephrology. 2011;16:290-8.
100. Kalil RS, Flanigan M, Stanford W, Haynes WG. Dissociation between progression of coronary artery calcification in hemodialysis patients: a prospective pilot study. Clin Nephrol. 2012;78:1-9.
101. Wada K, Wada Y. Evaluation of aortic calcification with lanthanum carbonate vs. calcium-based phosphate binders in maintenance hemodialysis patients with type 2 diabetes mellitus: an open-label randomized controlled trial. Ther Apher Dial. 2014;18:353-60.
102. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382:1268-77.
103. Komaba H, Kakuta T, Suzuki H, Hida M, Suga T, Fukagawa M. Survival advantage of lanthanum carbonate for hemodialysis patients with uncontrolled hyperphosphatemia. Nephrol Dial Transplant. 2015;30:107-14.
104. Tsuchida K, Nagai K, Yokota N, Minakuchi J, Kawashima S. Impact of lanthanum carbonate on prognosis of chronic hemodialysis patients: a retrospective cohort study (Kawashima Study). Ther Apher Dial. 2016;20:142-8.
105. Shigematsu T. Lanthanum Carbonate Research Group: three-year extension study of lanthanum carbonate therapy in Japanese hemodialysis patients. Clin Exp Nephrol. 2010;14:589-97.
106. Shigematsu T, Nakashima Y, Ohya M, Tatsuta K, Koreeda D, Yoshimoto W, et al. The management of hyperphosphatemia by lanthanum carbonate in chronic kidney disease patients. Int J Nephrol Renovasc Dis. 2012;5:81-9.
107. Shigematsu T, Ohya M, Negi S, Matsumoto AR, Nakashima YM, Iwatani Y, et al. Safety and efficacy evaluation of lanthanum carbonate in end-stage renal disease patients. Contrib Nephrol. 2015;185:42-55.
108. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, et al. The ADVANCE study: a randomized study to evaluate the effect of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant. 2011;26:1327-39.
109. Urena-Torres P, Bridges I, Christiano C, Counoyer SH, Cooper K, Farouk M, et al. Efficiency of cinacalcet with low-dose vitamin D in incidental hemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant. 2013;28:1241-54.
110. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, et al. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367:2482-94.
111. Moe SM, Chertow GM, Parfrey PS, Kubo Y, Block GA, Correa-Rotter R, et al. Cinacalcet, fibroblast growth factor 23, and cardiovascular disease in hemodialysis: the evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial. Circulation. 2015;132:27-39.
112. Parfrey P, Drüeke TB, Block GA, Correa-Rotter R, Floege J, Herzog CA, et al. The effects of cinacalcet in older and younger patients on hemodialysis: the evaluation of cinacalcet HCL therapy to lower cardiovascular events (EVOLVE) trial. Clin J Am Soc Nephrol. 2015;10:791-9.
113. Lau WL, Leaf EM, Hu MC, Takeno MM, Kuro-o M, Moe OW, et al. Vitamin D receptor agonists increase klotho and osteopontin while decreasing aortic calcification in mice with chronic kidney disease fed a high phosphate diet. Kidney Int. 2012;82:1261-70.
114. Mathew S, Lund RJ, Chaudhary LR, Geurs T, Hruska KA. Vitamin D receptor activators can protect against vascular calcification. J Am Soc Nephrol. 2008;19:1509-19.
115. Price PA. Gla-containing proteins of bone. Connect Tissue Res. 1989;21:51-7.
116. Holden RM, Booth SL, Day AG, Clase CM, Zimmerman D, Moist L, et al. Inhibiting the progression of arterial calcification with vitamin K in hemodialysis patients (iPACK-HD) trial: rationale and study design for a randomized trial of vitamin K in patients with end stage kidney disease. Can J Kidney Health Dis. 2015;2:17.
117. Caluwé R, Pyfferoen L, De Boeck K, De Vriese AS. The effects of vitamin K supplementation and vitamin K antagonists on progression of vascular calcification: ongoing randomized controlled trials. Clin Kideny J. 2016;9:273-9.
118. Hou SH, Zhao J, Ellman CF, Hu J, Griffin Z, Spiegel DM, et al. Calcium and phosphate fluxes during hemodialysis with low calcium dialysate. Am J Kidney Dis. 1991;18:217-24.
119. Ok E, Asci G, Bayraktaroglu S, Toz H, Ozkahya M, Yilmaz M, et al. Reduction of dialysate calcium level reduces progression of coronary artery calcification and improves low bone turnover in patients on hemodialysis. J Am Soc Nephrol. 2016;27:2475-86.
120. Nitta K, Akiba T, Suzuki K, Uchida K, Watanabe R, Majima K, et al. Effects of cyclic intermittent etidronate therapy on coronary artery calcification in patients receiving long-term hemodialysis. Am J Kideny Dis. 2004;44:680-8.
121. Hashiba H, Aizawa S, Tamura K, Shigematsu T, Kogo H. Inhibitory effects of etidronate on the progression of vascular calcification in hemodialysis patients. Ther Apher Dial. 2004;8:241-7.
122. Toussaint ND, Lau KK, Strauss BJ, Polkinghorne KR, Kerr PG. Effect of alendronate on vascular calcification n CKD stages 3 and 4: a pilot randomized controlled trial. Am J Kidney Dis. 2010;56:57-68.
123. Elmarish S, Delaney JA, Bluemke DA, Budoff MJ, O'Brien KD, Fuster V, et al. Associations of LV hypertrophy with prevalent and incident valve calcification: multi-ethnic study of atherosclerosis. JACC Cardiovasc Imaging. 2012;5:781-8.
124. Wheeler DC, Becker GJ. Summary of KDIGO guideline. What do we really know about management of blood pressure in patients with chronic kidney disease? Kidney Int. 2013;83:377-83.
125. Fukagawa M, Yokoyama K, Koiwa F, Taniguchi M, Shoji T, Kazama JJ, et al. Clinical practice guideline for the management of chronic kidney disease-mineral and bone disorder. Ther Apher Dial. 2013;17:247-88.
126. Mathews SJ, de Las FL, Podaralla P, Cabellon A, Zheng S, Bierhals A, et al. Effects of sodium thiosulfate on vascular calcification in end-stage renal disease: a pilot study of feasibility, safety and efficacy. Am J Nephrol. 2011;33:131-8.
127. Nigwekar SU, Brunelli SM, Meade D, Wang W, Hymes J, Lacson E. Sodium thiosulfate therapy for calcific uremic arteriolopathy. Clin J Am Soc Nephrol. 2013;8:1162-70.
128. Pasch A, Schffner T, Huynh-Do U, Frey BM, Frey FJ, Farese S. Sodium thiosulfate prevents vascular calcification in uremic rats. Kidney Int. 2008;74:1444-53.
129. Schlieper G, Brandenburg V, Ketteler M, Floege J. Sodium thiosulfate in the treatment of calcific uremic arteriolopathy. Nat Rev Nephrol. 2009;5:539-43.
130. Adirekkiat S, Sumethkul V, Ingsathit A, Domrongkitchaiporn S, Phakdeekitcharoen B, Kantachuvesiri S, et al. Sodium thiosulfate delays the progression of coronary artery calcification in haemodialysis patients. Nephrol Dial Transplant. 2010;25:1923-9.